Novartis' indacaterol plus Spiriva gives combined efficacy boost in COPD
This article was originally published in Scrip
Executive Summary
Using Novartis' once-daily Onbrez Breezhaler (indacaterol; formerly QAB149) plus tiotropium (Boehringer Ingelheim's Spiriva HandiHaler), provides significantly greater improvement in lung function than tiotropium alone in patients with chronic obstructive pulmonary disease (COPD), according to results from two Phase III studies.